IM Biologics (KRX: 493280)
Who is buying IM Biologics?
Between Sep 10, 2026 and Oct 13, 2026 (20 trading sessions), foreign investors net sold ₩4.9bn ($4M) of IM Biologics, the 104th largest foreign net sale among 1828 KOSDAQ stocks. Institutions net bought ₩0.9bn ($1M) and retail investors net bought ₩4.7bn ($4M) over the same window. Foreigners were net buyers on 4 of the 20 sessions.
Foreign investors hold 3.05% of IM Biologics' listed shares (KRX ownership data as of Oct 13, 2026), down from 4.88% twenty sessions earlier.
The stock closed at ₩15,680 on Oct 13, 2026: +2.62% over 20 sessions. The 52-week range is ₩13,190 – ₩104,000.
At ₩15,680 the stock trades at 122.50× trailing earnings (KRX, last completed fiscal year); no analyst consensus is available for a forward P/E.
View chart data as a table
| Date | Close | Foreign net | Institutions | Retail |
|---|---|---|---|---|
| 2026-10-13 | ₩15,680 | ₩-0.6bn | ₩-0.1bn | +₩0.8bn |
| 2026-10-12 | ₩17,240 | ₩-0.0bn | +₩0.1bn | ₩-0.0bn |
| 2026-10-08 | ₩18,460 | ₩-0.4bn | +₩0.0bn | +₩0.4bn |
| 2026-10-07 | ₩18,850 | ₩-0.9bn | ₩-0.1bn | +₩0.9bn |
| 2026-10-06 | ₩18,970 | +₩0.7bn | ₩-1.3bn | +₩0.6bn |
| 2026-10-02 | ₩17,140 | ₩-0.7bn | +₩0.1bn | +₩0.6bn |
| 2026-10-01 | ₩18,000 | +₩0.2bn | +₩0.0bn | ₩-0.2bn |
| 2026-09-30 | ₩16,470 | +₩0.3bn | ₩-0.4bn | +₩0.1bn |
| 2026-09-29 | ₩17,270 | ₩-0.3bn | +₩0.2bn | +₩0.1bn |
| 2026-09-28 | ₩17,670 | ₩-0.6bn | +₩0.3bn | +₩0.4bn |
| 2026-09-23 | ₩17,670 | ₩-0.2bn | +₩1.1bn | ₩-0.8bn |
| 2026-09-22 | ₩15,920 | +₩1.0bn | ₩-0.0bn | ₩-0.9bn |
| 2026-09-21 | ₩13,900 | ₩-0.4bn | ₩-2.5bn | +₩2.8bn |
| 2026-09-18 | ₩15,710 | ₩-0.1bn | +₩0.3bn | ₩-0.1bn |
| 2026-09-17 | ₩16,530 | ₩-0.2bn | +₩0.4bn | ₩-0.1bn |
| 2026-09-16 | ₩16,010 | ₩-0.2bn | +₩0.2bn | +₩0.1bn |
| 2026-09-15 | ₩16,300 | ₩-0.4bn | +₩0.6bn | ₩-0.1bn |
| 2026-09-14 | ₩16,200 | ₩-0.7bn | +₩0.7bn | +₩0.1bn |
| 2026-09-11 | ₩15,900 | ₩-0.6bn | +₩0.8bn | ₩-0.1bn |
| 2026-09-10 | ₩14,980 | ₩-0.7bn | +₩0.6bn | +₩0.1bn |
| 2026-09-09 | ₩15,280 | ₩-0.4bn | +₩0.3bn | +₩0.2bn |
| 2026-09-08 | ₩15,400 | +₩0.3bn | +₩0.4bn | ₩-0.5bn |
| 2026-09-07 | ₩14,550 | +₩0.1bn | ₩0.0bn | ₩-0.0bn |
| 2026-09-04 | ₩14,720 | +₩0.1bn | ₩-0.0bn | ₩-0.1bn |
| 2026-09-03 | ₩14,320 | ₩-0.1bn | ₩-0.0bn | +₩0.2bn |
| 2026-09-02 | ₩14,790 | ₩-0.0bn | +₩0.0bn | +₩0.1bn |
| 2026-09-01 | ₩15,300 | ₩-0.3bn | ₩-0.0bn | +₩0.3bn |
| 2026-08-31 | ₩16,080 | +₩0.1bn | +₩0.0bn | ₩-0.1bn |
| 2026-08-28 | ₩15,470 | ₩-0.1bn | +₩0.0bn | +₩0.1bn |
| 2026-08-27 | ₩15,750 | +₩0.2bn | +₩0.0bn | ₩-0.0bn |
| 2026-08-26 | ₩15,760 | +₩0.5bn | +₩0.0bn | ₩-0.3bn |
| 2026-08-25 | ₩15,300 | +₩0.2bn | ₩-0.0bn | ₩-0.1bn |
| 2026-08-24 | ₩15,030 | +₩0.3bn | ₩-0.1bn | ₩-0.1bn |
| 2026-08-21 | ₩15,160 | ₩-0.9bn | +₩0.0bn | +₩0.9bn |
| 2026-08-20 | ₩17,260 | +₩0.3bn | ₩0.0bn | ₩-0.3bn |
| 2026-08-19 | ₩16,890 | +₩0.1bn | +₩0.0bn | ₩-0.1bn |
| 2026-08-18 | ₩17,300 | ₩-0.8bn | ₩-0.0bn | +₩0.9bn |
| 2026-08-14 | ₩19,030 | +₩0.2bn | ₩-0.0bn | ₩-0.2bn |
| 2026-08-13 | ₩18,840 | +₩0.5bn | ₩-0.3bn | ₩-0.1bn |
| 2026-08-12 | ₩19,110 | +₩0.3bn | ₩-0.2bn | ₩-0.0bn |
| 2026-08-11 | ₩19,270 | +₩0.1bn | +₩0.1bn | ₩-0.0bn |
| 2026-08-10 | ₩19,250 | +₩0.2bn | +₩0.0bn | ₩-0.1bn |
| 2026-08-07 | ₩18,320 | ₩-0.2bn | +₩0.0bn | +₩0.2bn |
| 2026-08-06 | ₩19,100 | ₩-0.4bn | +₩0.2bn | +₩0.4bn |
| 2026-08-05 | ₩18,250 | +₩0.0bn | ₩-0.0bn | +₩0.1bn |
| 2026-08-04 | ₩17,330 | +₩0.0bn | +₩0.0bn | +₩0.1bn |
| 2026-08-03 | ₩16,160 | +₩0.2bn | ₩-0.0bn | ₩-0.0bn |
| 2026-07-31 | ₩15,310 | +₩0.4bn | ₩-0.1bn | ₩-0.1bn |
| 2026-07-30 | ₩13,800 | +₩0.1bn | ₩-0.0bn | +₩0.0bn |
| 2026-07-29 | ₩14,070 | +₩0.1bn | ₩-0.1bn | ₩-0.0bn |
| 2026-07-28 | ₩15,980 | +₩0.1bn | +₩0.0bn | ₩-0.1bn |
| 2026-07-27 | ₩17,660 | +₩0.3bn | ₩-0.0bn | ₩-0.2bn |
| 2026-07-24 | ₩17,100 | ₩-0.1bn | +₩0.1bn | +₩0.0bn |
| 2026-07-23 | ₩17,890 | +₩0.6bn | ₩-0.0bn | ₩-0.5bn |
| 2026-07-22 | ₩16,300 | +₩0.4bn | ₩-0.3bn | ₩-0.0bn |
| 2026-07-21 | ₩16,520 | +₩0.3bn | ₩-0.0bn | ₩-0.2bn |
| 2026-07-20 | ₩17,100 | ₩-0.0bn | ₩-0.0bn | +₩0.1bn |
| 2026-07-16 | ₩19,170 | +₩0.2bn | +₩0.0bn | ₩-0.1bn |
| 2026-07-15 | ₩19,660 | +₩0.5bn | ₩-0.1bn | ₩-0.4bn |
| 2026-07-14 | ₩18,720 | ₩-0.5bn | ₩-0.0bn | +₩0.6bn |
| 2026-07-13 | ₩19,900 | +₩0.2bn | ₩-0.1bn | +₩0.0bn |
Investor flows summary
| Window | Foreign | (USD) | Institutions | Retail |
|---|---|---|---|---|
| 1 day | ₩-0.6bn | $-0M | ₩-0.1bn | +₩0.8bn |
| 5 days | ₩-1.2bn | $-1M | ₩-1.3bn | +₩2.7bn |
| 20 days | ₩-4.9bn | $-4M | +₩0.9bn | +₩4.7bn |
Positive = net buying, negative = net selling. Values aggregate the KRX main board and the NXT alternative venue.
Frequently asked questions
Are foreign investors buying IM Biologics stock?
Over the last 5 sessions foreign investors net sold ₩1.2bn ($1M) of IM Biologics; over 60 sessions they net sold ₩2.2bn ($2M); since Jan 1, 2026 they net bought ₩5.8bn ($4M). Over 20 sessions the stock is the 104th largest foreign net sale among 1828 KOSDAQ stocks.
How much of IM Biologics do foreign investors own?
Foreign investors own 3.05% of IM Biologics' shares as of Oct 13, 2026. The figure is KRX's daily foreign holdings divided by listed shares, and it reflects trades settled through the previous session.
Who is on the other side — institutions or retail investors?
Over 20 sessions institutions net bought ₩0.9bn ($1M) and retail investors net bought ₩4.7bn ($4M) of IM Biologics. Foreign selling is being absorbed mainly by retail buying.
Is IM Biologics listed on KOSPI or KOSDAQ?
IM Biologics (아이엠바이오로직스) trades on KOSDAQ under KRX code 493280 in the Biotech & Pharma group, with a market capitalization of ₩0T ($0.2B). Daily net flows by investor type are published by KRX after each session and combine the KRX main board with the NXT venue.